IBRX — ImmunityBio, Inc.

—
Nasdaq · Health Care · Biotechnology · CIK 1326110 ·
Last close
$6.26
Market Cap
$6.66B
52W High
$12.43
52W Low
$1.95
ADV30
14,214,052
Next earnings
2026-11-09
ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead biologic product candidate includes Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors; and 3M-052, a synthetic TLR7/8 agonist and 3M-052 formulations and related technology. The company has collaboration agreements with National Cancer Institute; Serum Institute of India Private Limited; and BeOne Medicines Ltd. It has license agreement with 3M Innovative Properties Company and Access to Advanced Health Institute. ImmunityBio, Inc. is based in San Diego, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 48,841,000 47,550,000 -77,987,000 -184,550,000 609,391,000 45,082,000 1,754,831,000
Jun 2026 51,240,000 50,942,000 -61,697,000 -230,378,000 628,504,000 75,670,000 1,674,265,000
Mar 2026 44,206,000 43,968,000 -69,791,000 -632,782,000 646,637,000 205,194,000 1,515,763,000
Dec 2025 38,285,000 37,903,000 -64,683,000 -61,944,000 501,898,000 88,334,000 1,001,472,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-287,564,000
Investing CF
$-103,589,000
Financing CF
$376,297,000
CapEx
$-9,528,000
Dividends Paid
$0
Buybacks
—
EPS Diluted TTM
$-1.08
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-4,774,356,000
Inventory
$6,000
Receivables
$53,611,000
ST Investments
$289,247,000
EBIT TTM
$-990,919,000
Pretax Income TTM
$-1,109,836,000
Interest Exp TTM
$118,917,000
Analysts
4

Yahoo Snapshot (yfinance, live)

Total Revenue
$182,572,000
EBITDA
$-257,716,992
Free Cash Flow
$-176,333,872
Enterprise Value
$7,366,854,144
Total Cash
$334,328,992
Total Debt
$1,296,097,024
Shares Out
1,063,826,073
Trailing EPS
$-1.06
Book Value
$-1.08
ROE
—
ROA
-30.4%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 113,288,000 -256,027,000 -351,398,000 501,898,000 1,001,472,000 -500,469,000 -304,936,000
Dec 2024 14,745,000 -344,182,000 -413,564,000 382,933,000 871,062,000 -489,098,000 -391,236,000
Dec 2023 622,000 -361,364,000 -583,196,000 504,452,000 1,090,389,000 -586,987,000 -366,757,000
Dec 2022 240,000 -350,617,000 -416,567,000 362,356,000 812,176,000 -447,327,000 -337,509,000

TTM Snapshot

Revenues TTM
$165,792,000
NetIncome TTM
$-992,357,000
OpCashFlow TTM
—
Assets (Latest)
$628,504,000
Forward EPS
$-0.11

Max Pain — expiry 2026-11-27

max pain strike: $7.00 · spot: $6.70 · call oi: 2,477 · put oi: 2,528
Expected Move to 2026-11-27: ±$1.43 (21.27%) — implied range $5.28 – $8.12 · ATM straddle on $6.50 strike

Peers — same industry

TickerNameMarket CapLastDaily %
IMVT Immunovant, Inc. $6.87B $33.21 —
CGON CG Oncology, Inc. $7.00B $78.94 —
KOD Kodiak Sciences Inc. $6.33B $96.80 —
TWST Twist Bioscience Corp $7.43B $112.00 —
SRRK Scholar Rock Holding Corp $5.50B $45.08 —

News headlines (Yahoo Finance, 1h cache)

IBRX CEO Reveals Fresh Anktiva Data After Bladder Cancer Trial Win — Says FDA Filing Is Just Weeks Away
2026-11-17 06:38 · Yahoo
SLS, IBRX And IOVA Join Merck And Lilly On BlackRock’s Q3 Buy List — A Vanguard Unit Adds All Of Them Too
2026-11-16 07:31 · Yahoo
IBRX Stock In Focus As Institutional Investor Boosts Stake By Over 15% In Q3 — All Eyes On ImmunityBio’s London Conferences Next Week
2026-11-13 17:28 · Yahoo
IBRX Stock Eyes Best Year Ever: Founder Teases 12 Months Of ‘Stealth’ NantWorks Reveals — Cancer Tech, AI Chips And Satellites
2026-11-13 01:20 · Yahoo
ImmunityBio (IBRX) is Declining For 4 Days Now. What’s Triggering the Selloff?
2026-11-13 00:48 · Yahoo
IBRX Stock Eyes Worst Week In Nearly 2 Years — But Anktiva’s Sepsis Trial Potential Fuels Retail Bets On Big Pharma Appeal
2026-11-12 03:52 · Yahoo
What Could ImmunityBio (IBRX) Gain From ANKTIVA Label Expansion And Global Rollout?
2026-11-12 02:15 · Yahoo
ImmunityBio to Participate in UK Investor Conferences During London Life Sciences Week 2026
2026-11-11 02:31 · Yahoo
ImmunityBio shares slump 19% as revenue misses and going-concern warning hits sentiment
2026-11-09 16:44 · Yahoo
IBRX Stock Crashes To Near 9-Month Lows On Q3 Earnings Miss – Retail Says No Way To Escape Further Dilution
2026-11-09 14:36 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.